Redmile Group is a San Francisco-based investment firm founded in 2007 that specializes in healthcare and life sciences investments, including biotechnology, medical devices, and therapeutics. The firm makes venture, growth, and crossover investments across the healthcare sector.
43% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $103.6M (across 129 rounds with reported amounts).
Portfolio
105
Fund Size
$122M
Top Stage
Series B
Last 12 Mo
4
Team
AN
Amrit Nagpal
Managing Director/Partner
DF
Dillon Flinn
Managing Director
LF
Laura Feinleib
Managing Director
MF
Ming Fang
Managing Director
NB
Natalie Berner
Managing Director
RF
Rob Faulkner
Managing Director
JG
Jeremy Green
Founder and Portfolio Manager
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
143 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ambrosia Biosciences Inc. | Series B | $100M | Mar 2026 |
| AAvere Therapeutics | Unknown | $320M | Jan 2026 |
 Ambrosia Bio | Series B | $100M | Jan 2026 |
 Bambusa Therapeutics | Series A | — | Nov 2025 |
 Electra | Series C | $183M | Oct 2025 |
| EElectra Therapeutics | Series C | $183M | Oct 2025 |
 One Biosciences | Series A | — | Jul 2025 |
 Home Biosciences | Series A | — | Jul 2025 |
| Bambusa Therapeutics | Series A | $90M | Feb 2025 |
 Abcuro, Inc. | Series C | $200M | Feb 2025 |
 Star Therapeutics | Series D | $125M | Jan 2025 |
 RAPT Therapeutics | Series D | $150M | Dec 2024 |
 Lycia Therapeutics | Series C | $106.6M | May 2024 |
 Attovia Therapeutics | Series B | $105M | May 2024 |
 Denali Therapeutics | Series C | $217M | Mar 2024 |
 Impulse Dynamics | Unknown | $136M | Feb 2024 |
 Neurogene | Series B | $115M | Jan 2024 |
 Employer Direct Healthcare | Growth | $92M | Dec 2023 |
| AAgomab | Series B | $100M | Oct 2023 |
 ADARx Pharmaceuticals | Series C | $200M | Aug 2023 |
 Orbital Therapeutics | Series A | $270M | Apr 2023 |
 Deciphera Pharmaceuticals | Series C | $52M | Jan 2023 |
 Zentalis | Series C | $85M | Jan 2023 |
| AAdarx | Series C | $46M | Jan 2023 |
| EElectra Therapeutics | Series B | $84M | Feb 2022 |
Page 1 of 6
Top Co-Investors
Cormorant Asset Management28 shared
Perceptive Advisors23 shared
OrbiMed23 shared
Casdin Capital22 shared
RA Capital Management21 shared
The Invus Group, LLC21 shared
GV18 shared
Foresite Capital16 shared
Omega Funds16 shared
Samsara BioCapital16 shared
Wellington Management16 shared
Surveyor Capital14 shared
Alexandria Venture Investments14 shared
Logos Capital14 shared
Cowen Healthcare Investments13 shared
Sanofi Ventures13 shared
Bain Capital Life Sciences13 shared
Viking Global Investors12 shared
ArrowMark Partners11 shared
New Leaf Venture Partners10 shared
Last updated: 7 October 2026